SCHEMBL24918878

SCHEMBL24918878

CC(C)(C)CCOCCOCCOCCOCCNC(=O)CCOCCOCCC(C)(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
CA2 P00918 5/20 0.38
CA12 O43570 4/20 0.38
CA1 P00915 4/20 0.38
CA4 P22748 4/20 0.38
CA9 Q16790 4/20 0.38
CA14 Q9ULX7 4/20 0.38
TSHR P16473 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.35
PIK3CG P48736 1/20 0.35
SIGMAR1 Q99720 2/20 0.35
KDM4E B2RXH2 1/20 0.34
GLA P06280 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
HDAC3 O15379 1/20 0.33
HDAC1 Q13547 1/20 0.33
ALDH1A1 P00352 1/20 0.32
RECQL P46063 1/20 0.32
CASP2 P42575 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24918920 1.00 MEN1 (0.42) MEN1KMT2ACA2CA12CA1
SCHEMBL24918884 0.94 SMN1; SMN2 (0.39) MEN1KMT2ACA2CA12CA1
SCHEMBL26364039 0.93 SIGMAR1 (0.41) MEN1KMT2ACA2CA12CA1
SCHEMBL25746260 0.93 MEN1 (0.42) MEN1KMT2ACA2CA12CA1
SCHEMBL21579901 0.92 MEN1 (0.37) MEN1KMT2ACA2CA12CA1
SCHEMBL22959796 0.91 SIGMAR1 (0.42) MEN1KMT2ATSHRSMN1; SMN2PIK3CG
SCHEMBL25876065 0.91 TSHR (0.39) MEN1KMT2ACA2CA12CA1
SCHEMBL24193584 0.90 TSHR (0.43) MEN1KMT2ATSHRSMN1; SMN2SIGMAR1
SCHEMBL22629758 0.90 TSHR (0.43) MEN1KMT2ACA2CA12CA1
SCHEMBL24982782 0.88 CA12 (0.39) MEN1KMT2ACA2CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230028880-A1 CD38-BINDING AGENTS AND USES THEREOF KLEO PHARMACEUTICALS, INC. 2023-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230028880-A1 CD38-BINDING AGENTS AND USES THEREOF CD38, CD47, CD2 MEN1 3315/4885KMT2A 1286/4885CA2 2170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.